Effects of hemodialysis on circulating adrenomedullin concentrations in patients with end-stage renal disease by Toepfer, Marcel et al.
Original Paper
Blood Purif 1998;16:269–274
Effects of Hemodialysis on
Circulating Adrenomedullin
Concentrations in Patients with
End-Stage Renal Disease
M. Toepfera
M. Schlosshauerb
T. Sitter a
C. Burchardia
T. Behr c
H. Schiffla
Departments of
a Nephrology,
b Clinical Pharmacology, and
c Cardiology, Medizinische Klinik,
Klinikum Innenstadt
Ludwig Maximillians University,
Munich, Germany
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Key Words
Adrenomedullin
End-stage renal disease
Hemodialysis
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Abstract
To characterize the determinants of circulating levels of adre-
nomedullin (AM), the plasma levels of this peptide were mea-
sured in 58 patients with end-stage renal disease on hemodial-
ysis. Predialysis plasma levels of AM were more than twice as
high in patients on hemodialysis as compared to controls. In
hemodialysis patients with heart failure (NYHA classes II–IV)
or hypertensive HD patients plasma levels of AM were signifi-
cantly higher than in patients with end-stage renal disease
only. Plasma levels of AM were not altered immediately by
hemodialysis but decreased significantly 14–20 h after hemo-
dialysis. AM plasma levels before hemodialysis and 14–20 h
after hemodialysis were correlated with the corresponding
mean arterial pressure.
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Introduction
Human adrenomedullin (AM) is a 52-ami-
no-acid peptide which was first isolated from
pheochromocytoma tissue, but AM has also
been found in other organs, as well as in plas-
ma [1–3]. These notions suggest that AM may
not only be a paracrine or autocrine peptide
but also a circulating hormone. The physio-
logical effects and pathobiological mecha-
nisms of AM in man are not yet known. How-
ever, among the multiple pharmacological ef-
fects of AM observed in experimental ani-
mals, a major hypothesis has emerged that of
a common effector of the coordinated systems
by which fluid and electrolyte homeostasis
and vascular tone are maintained [4–7]. Plas-
ma levels of AM are increased in renal failure,
and circulating AM correlates with plasma
creatinine [8, 9]. The origins of the markedly
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elevated AM levels in end-stage renal disease,
which are 2- to 5-fold higher than the levels in
healthy subjects are not fully known. There is
no doubt that decreased renal clearance of
AM may contribute to the raised AM concen-
trations. However, circulating AM levels may
differ substantially among patients with end-
stage renal disease. Of note are the correla-
tions between plasma AM levels and atrial
natriuretic factor, both in congestive heart
failure and chronic failure [10, 11], suggesting
that volume expansion may be a stimulus for
enhanced synthesis or secretion of AM in
patients with end-stage renal disease. How-
ever, dialysis-induced contraction of extracel-
lular fluid volume failed to alter AM levels in
patients receiving hemodialysis [9].
The objectives of the present study were
(a) to measure the predialysis AM levels in
relation to coexistent diseases, (b) to establish
correlations between plasma AM levels and
corresponding predialysis volume-dependent
blood pressure levels, and (c) to re-evaluate
the effects of dialysis-induced volume con-
traction of postdialysis plasma AM concentra-
tions.
Materials and Methods
Study Population
Fifty-eight patients with end-stage renal disease
receiving regular hemodialysis were enrolled in the
study (36 men, 22 women; mean age 61 B 15 years,
range 20–84 years). They all gave written consent to
participate in these investigations, which were ap-
proved by the local ethical committee. The cause of
chronic renal failure was glomerulonephritis in 16
patients, diabetic nephropathy in 14, nephrosclerosis
in 5, tubulointerstitial nephritis in 5, polycystic disease
in 4, systemic vasculitis in 2 and renal disease of
unknown origin in 12. Twenty-four healthy subjects
(14 men, 10 women; mean age 56 B 16 years, age
range from 22 to 68 years) served as controls. Twenty-
one patients with end-stage renal disease had chronic
arterial hypertension (blood pressure reading was con-
sistently over 140/90 mm Hg), 20 patients suffered
from coexistent heart failure (New York Heart Asso-
ciation II–IV). None of the patients had liver cirrhosis
or chronic obstructive pulmonary disease.
Study Design
Predialysis Plasma AM in Patients with End-Stage
Renal Disease. Prior to a regularly scheduled hemodi-
alysis session, patients remained supine for 15 min
before blood samples were taken from the arteriove-
nous fistula. Blood pressure and pulse rate were mea-
sured before blood samples were taken.
Effect of Hemodialysis on Plasma AM Levels. He-
modialysis was performed three times per week for 4–
5 h with volumetrically controlled ultrafiltration de-
vices (Fresenius MTS 2008 or 4008, dialysate flow
500 ml/min, blood flow rates of 200–250 ml/min).
Fluid removal rates were adjusted to clinical needs. All
patients underwent bicarbonate dialysis utilizing low-
flux hemodialyzers (F6 low-flux polysulfone Fresenius,
Bad Homburg, Germany, surface 1.25 m2, UF coeff.
5.5 ml/h ! mm Hg, urea clearance 183 ml/min, B12
clearance 56 ml/min). None of the patients received
intradialytic fluid replacement or antihypertensive
drugs. At the end of the dialysis session (immediately
prior the backwash fluid substitution, postdialysis
blood samples were taken in all 58 patients. In 16 of
the study patients further blood samples were taken
the morning after the hemodialysis session (14–20 h
after hemodialysis).
Laboratory Methods. Blood was collected in tubes
containing 1 mg/ml disodium EDTA and 500 U/ml
aprotinin. Samples were centrifuged immediately at
4°C and the plasma was frozen and stored at –80 °C
pending the assay. Plasma levels of AM were measured
by specific radioimmunoassay after extraction using
C-18 Sep-Pak cartridges (AM-RIA Kit and cartridges
from Phoenix Pharmaceuticals Inc., Mountain View,
Calif., USA). The intra-assay and interassay coeffi-
cients of variation were !5 and 8%, respectively. The
detection limit for the assay was 3.01 pg/ml, the half-
maximal inhibition dose of radioiodinated binding by
AM was 46 pg/tube. The maximal and minimal con-
centrations detected by the assay were 240 and
3.01 pg/ml, respectively. The radioimmunoassay had
100% cross-reactivity with human AM 1–52 and no
cross-reactivity with AM 13–52 calcitonin gene-related
peptide and amylin.
Statistical Analysis
Mean arterial pressure was calculated by the stan-
dard formula. Data are given as mean B standard
deviation (SD). Postdialysis AM concentrations were
corrected for ultrafiltration. The results of the groups
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Fig. 1. Plasma concentrations
of AM in controls and in patients
with end-stage renal disease before
and after hemodialysis (HD) (un-
corrected for ultrafiltration) (mean
B SD); n.s. = not significant.
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or subgroups were analyzed and compared by the
Mann-Whitney U test and correlation tests. p values
!0.05 were considered significant.
Results
The demographic characteristics of the pa-
tients with end-stage renal disease and healthy
controls are given in table 1. There were no
statistically significant differences between
patients and controls with respect to age and
body weight. Compared to age- and body-
weight-matched healthy subjects, hemodialy-
sis patients had significantly higher mean sys-
tolic and diastolic blood pressure values. He-
modialysis patients had significantly in-
creased plasma AM levels (67.9 B 15.4 vs.
27.1 B 4.6 pg/ml; p ! 0.001; fig. 1). There
were significant differences in circulating AM
between subgroups of hemodialysis patients.
Plasma AM levels were 58.0 B 13.2 pg/ml in
normotensive patients on hemodialysis, 71.4
B 15.4 pg/ml in hypertensive patients on he-
modialysis, 74.3 B 14.9 pg/ml in normoten-
sive hemodialysis patients with heart failure
and 76.8 B 9.6 pg/ml in hypertensive hemo-
Table 1. Basal clinical and laboratory data of HD-
patients and controls
Healthy
subjects
(n = 24)
Patients
on HD
(n = 58)
56.2B14.5 61.4B15.8
Body weight, kg 68.8B10.4 63.1B12.5a
SAP, mm Hg 122B18 147B28a
DAP, mm Hg 70B8 78B14a
MAP, mm Hg 88B11 101B17a
Pulse rate min 70B3 77B6a
Serum creatinine, mg/dl 0.7B0.2 7.5B2.3a,b
Values are expressed as mean B SD. HD = Hemo-
dialysis; SAP = systolic arterial pressure; DAP = dia-
stolic arterial pressure; MAP = mean arterial pressure.
a p ! 0.05 vs. healthy subjects; b p ! 0.05 vs. prehe-
modialysis values.
dialysis patients with heart failure. There
were significant correlations between systolic
and mean arterial pressure and predialysis
plasma AM concentrations in all patients
studied (fig. 2).
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Fig. 2. AM plasma levels in pa-
tients with end-stage renal disease
before hemodialysis (HD) in corre-
lation with systolic arterial pres-
sure (SAP) and mean arterial pres-
sure (MAP).
Fig. 3. Plasma levels of AM in a
subgroup of 16 patients with end-
stage renal disease before hemodi-
alysis, after hemodialysis (uncor-
rected for ultrafiltration) and the
next morning (14–20 h after hemo-
dialysis); n.s. = not significant.
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Hemodialysis-induced ultrafiltration re-
sulted in a significant reduction of body
weight (2.4 kg), a significant fall in blood pres-
sure values and a significant rise in pulse rate.
However, hemodialysis did not acutely affect
plasma AM levels in our population of 58
patients receiving hemodialysis. Correction of
postdialysis plasma AM for ultrafiltration-
induced contraction of intravascular volume
revealed a slight but not statistically signifi-
cant rise in plasma AM as compared to pre-
dialysis patients. Despite a slight gain in body
weight (0.9 kg) measurement of plasma AM
14–20 h after the hemodialysis session
showed a significant reduction in plasma AM
concentration as compared to predialysis or
the first postdialysis plasma AM concentra-
tion even for corrected plasma AM concentra-
tion (table 2, fig. 3).
Age, years
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Table 2. Basal clinical and laboratory data of 16 patients investigated 14–20 h after HD
Pre-HD Immediately
post-HD
14–20 h
post-HD
55.9B19.2
Body weight, kg 61.3B11.4 58.9B10.3a 59.8B9.2
SAP, mm Hg 142.3B22.2 134.6B14.8a 137.8B14.9a
DAP, mm Hg 86.2B10.1 80.8B9.0 84.4B8.3
MAP, mm Hg 101.1B17.7 94.5B15.4a 97.9B12.9
Pulse rate/min 78.9B6.6 88.3B9.1a 80.0B7.7b
Serum creatinine, mg/dl 8.4B3.2 4.1B2.8a 5.6B3.1a,b
Values are expressed as mean B SD. a p ! 0.05 vs. prehemodialysis values; b p ! 0.05 vs.
posthemodialysis values.
Discussion
The major result of our investigation dem-
onstrates that the circulating AM concentra-
tion in patients with end-stage renal disease
receiving regular hemodialysis may not be
determined by a single factor, but may be the
result of different interacting mechanisms.
Confirming previous reports on plasma AM
in end-stage renal patients, predialysis levels
were significantly increased [8, 9]. To date,
the mechanisms of circulating AM elevation
in human chronic renal failure remain unde-
fined. Synthesis, secretion, metabolism and
clearance of AM have not been elucidated.
However, AM may play a role in regulating
water and electrolyte excretion by the kidney
through release of endogenous NO [5]. Since
other peptide hormones or small fragments of
peptides are known to be metabolized in the
kidneys or excreted by the kidneys into the
urine, the possibility of a decreased clearance
of AM in renal failure patients cannot be
excluded as an explanation for the elevated
AM observed in end-stage renal disease pa-
tients. In fact, other investigators reported
that plasma AM concentrations are positively
correlated with serum creatinine and inverse-
ly correlated with the glomerular filtration
rate [9]. Sato et al. [12] characterized immu-
noreactive AM in human plasma and urine.
In 5 normal subjects, immunoreactive urinary
AM was found at 5–6 times the concentration
present in plasma. Thus, AM found in the
urine, may come from the plasma or be pro-
duced within the kidneys. However, circulat-
ing AM levels in our patients differed signifi-
cantly between patients with uncomplicated
end-stage renal disease and patients with
coexistent cardiovascular disorders. The high-
er AM levels found in the latter subgroup of
patients confirm previous reports of increased
plasma AM levels in patients with congestive
heart failure or arterial hypertension but nor-
mal renal function [9, 11, 13]. There is grow-
ing evidence that cardiac secretion of AM
occurs in human heart failure. Of note is the
observation that AM plasma levels correlate
with parameters of the sympathetic nervous
system [14, 15] as well as with markers of vol-
ume status [11].
The current study confirms that hemodial-
ysis with or without ultrafiltration does not
alter circulating AM levels, whether or not
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plasma AM levels taken at the end of the dial-
ysis session are corrected for volume concen-
tration. There is no doubt that the peptide
AM (molecular weight 6.028) poorly passes
low-flux hemodialyzer membranes. However,
Mallamaci et al. [16] provided preliminary
evidence that isolated ultrafiltration may re-
duce plasma AM levels, and in our study late
measurements of plasma AM revealed signifi-
cantly lower AM levels in a subgroup of pa-
tients. Therefore secretion of AM seems to be
increased in response to expansion of extra-
cellular fluid volume overload in end-stage
renal disease and may contribute to the high
plasma AM levels. Dialysis-induced ultrafil-
tration may induce a counteracting stimula-
tion of the sympathetic nervous system activi-
ty which may mask the effect of ultrafiltration
on plasma AM levels.
Although AM levels are elevated in human
diseases such as end-stage renal disease, direct
cause and effect relationships have not been
established. Moreover, clear definitions of the
roles AM in health or kidney diseases are
needed.
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